about
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.Prediction of early breast cancer metastasis from DNA microarray data using high-dimensional cox regression modelsAn R function to non-parametric and piecewise analysis of competing risks survival data.Prognosis and ICU outcome of systemic vasculitisSingle domain antibodies with VH hallmarks are positively selected during panning of llama (Lama glama) naïve libraries.DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instabilityDosimetric comparison between helical tomotherapy and volumetric modulated arc-therapy for non-anaplastic thyroid cancer treatment.Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma.Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary.Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer--the INNODIAG studyGuidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma.Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancerBody Composition and Anti-Neoplastic Treatment in Adult and Older Subjects - A Systematic Review.Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytesKey contribution of eIF4H-mediated translational control in tumor promotion.Recurrence risk after Ivor Lewis oesophagectomy for cancerThe AF-1-deficient estrogen receptor ERα46 isoform is frequently expressed in human breast tumorsPostoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study.Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.Conventional versus automated implantation of loose seeds in prostate brachytherapy: analysis of dosimetric and clinical results.Prospective construction and validation of a prognostic score to identify patients who benefit from third-line chemotherapy for metastatic breast cancer in terms of overall survival: the METAL3 Study.Pelvic exenterations for specific extraluminal recurrences in the era of total mesorectal excision: is there still a chance for cure?: a single-center review of patients with extraluminal pelvic recurrence for rectal cancer from March 2004 to NovembEvaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.Optimal scheduling of post-therapeutic follow-up of patients treated for cancer for early detection of relapses.Anatomical correlates for category-specific naming of objects and actions: a brain stimulation mapping study.A Systematic Review and Meta-Analysis of Double Venous Anastomosis in Free Flaps.Cell-assisted lipotransfer: friend or foe in fat grafting? Systematic review and meta-analysis.Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review.Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung.Malignant Peripheral Nerve Sheath Tumor Is a Challenging Diagnosis: A Systematic Pathology Review, Immunohistochemistry, and Molecular Analysis in 160 Patients From the French Sarcoma Group Database.Statistical controversies in clinical research: should schedules of tumor size assessments be changed?Long-term oncological outcome after endoscopic surgery for olfactory esthesioneuroblastoma.Goodness-of-fit test for monotone proportional subdistribution hazards assumptions based on weighted residuals.Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations.
P50
Q27027579-493FBAA0-8A6A-4381-B3B1-FBEF941E5E78Q27853124-31F0E4D6-96E8-4FC7-A84C-B1E16ADA6B7DQ27853282-027287F2-0987-487B-A531-FE2B3EC63F21Q30953190-934053CA-E314-49CB-B8C9-09585D4C62A6Q33546245-00180789-46CE-4F86-A0AA-CF00562DD617Q33591594-49A81CAE-A236-4746-9349-C9557CEC0279Q33964591-AFC52633-56B9-48D6-99B7-FB24200AD50DQ34067829-BD160196-5A8F-4609-A2EB-7F19B7500E9DQ34611481-D00DECF4-228F-4F77-812A-F9287667BA91Q34959939-4AC8791E-A2E5-4706-A196-A76989DA6C55Q34990489-216BC263-91E1-4801-AB14-79E9DC5CC8F5Q35125752-60AC1EF0-6069-42FF-A833-9A1FB850CADDQ35214578-C02653BC-9C0B-4BEB-BC12-E0BA9340C5C1Q35544960-75761C0A-11EA-4996-BF2E-2AD158CCEF54Q35907074-EE4984A6-5F02-49F0-8A95-4AB003E2251CQ36042621-618102AF-717E-430B-80F6-A6E1BA68475BQ36154581-34BD1C1D-1BFB-45C9-AE02-90117589EB26Q36233937-7724890F-312A-4B9E-B63E-307B6E327DDDQ36373347-7E2C5674-F1FA-495D-983F-73836C1B6023Q36545515-12278DAC-22CB-4B25-B9C2-4671826AB1E6Q37479830-6B56B37D-431A-464C-A974-0D1FDDA3F4E9Q37481267-6F7192EE-BB41-47CD-990C-102A6ED14C90Q37822609-0B4A489C-827C-4AF9-84DC-4CA6FAEA0713Q38057500-D7D8C1EF-5523-4A72-8AD4-0560D2E4B135Q38153861-8BF9FF7C-5729-48E6-98BC-2C7C2921865DQ38280530-650B631E-C9E1-4598-AD59-B9C0A2BABD2BQ38294049-0146E82E-A89C-4697-A6F6-5BF64A5E63DEQ38419387-854EBDAD-2E10-4B8C-8073-AFD42E7E9A79Q38422132-D2EBAB1E-FD8A-4841-8BC1-117F12B738AEQ38463611-95B40E3C-1449-41BF-99DF-070E5DE9225DQ38643328-35F31A92-F315-4447-8730-1764ACE2ADDEQ38673615-031358F5-09A0-4513-8782-CCC3B5523E01Q38794973-C8CC6A76-30D7-40DB-8254-9C9E10EE74F3Q38815101-0A765C9A-971D-441F-9967-B02FE8BB38A3Q38829522-169F42C4-8C3A-422B-ABC1-59CFCE4343ECQ38922196-6EF1674B-40E9-46D4-A81F-FDCD126A29ECQ39097595-138F3939-ECF9-4DFD-8DC9-5F86FDF6C76FQ39240242-C3173214-13A6-467B-822F-FF150D1CB12AQ39275138-3AE10E20-9745-4FBF-872C-54E6B40B38ACQ39480070-AA5FD456-17B4-4DB7-8569-B6B0BC8B7579
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thomas Filleron
@ast
Thomas Filleron
@en
Thomas Filleron
@es
Thomas Filleron
@nl
Thomas Filleron
@sl
type
label
Thomas Filleron
@ast
Thomas Filleron
@en
Thomas Filleron
@es
Thomas Filleron
@nl
Thomas Filleron
@sl
prefLabel
Thomas Filleron
@ast
Thomas Filleron
@en
Thomas Filleron
@es
Thomas Filleron
@nl
Thomas Filleron
@sl
P106
P1153
11840316600
P21
P2456
P31
P496
0000-0003-0724-0659